• Lung cancer represents the most incident cancer worldwide and is the leading cause of cancer death in both more and less developed countries. 1 • In Brazil, it was estimated that 27,330 new cases of lung cancer would occurred in 2016 1 . However, few studies report treatment patterns regarding NSCLC in the country.
Introduction
• Lung cancer represents the most incident cancer worldwide and is the leading cause of cancer death in both more and less developed countries. 1 • In Brazil, it was estimated that 27,330 new cases of lung cancer would occurred in 2016 1 . However, few studies report treatment patterns regarding NSCLC in the country.
• Despite high burden of NSCLC, sparse data on resource use and treatment patterns of the disease in Brazilian private healthcare hamper decision-making process due to increased uncertainty in disease knowledge, treatment patterns and costs impact
Objectives
• This real-world study describes the patterns of care and clinical profile of advanced NSCLC (aNSCLC), in addition to the use of resources during treatment and evaluate prognostic factors, in 6 of Brazilian private health care institutions.
Methods
• Data from medical charts were retrospectively collected from six private institutions in Brazil, with Ethics Committees approval of all institutions involved. • Key eligibility criteria included patients older than 18 years at the time of diagnosis (or recurrence), documented diagnosis of advanced (stages IIIB and IV) or recurrent NSCLC between January 2011 and July 2014 and having received at least two chemotherapy treatment lines. The follow-up period was determined until the end of inclusion period (03/03/17).
• Statistical analyses were performed using software R®.
• Data were summarized by measures of central tendency and dispersion and in absolute and relative frequencies. Survival analysis from aNSCLC diagnosis date was performed using Cox regression modelling.
Results
• Out of 430 charts of patients with NSCLC screened, 152 (non-squamous=121, squamous=26, unknown=5) were eligible. Patients' demographic and clinical characteristics are described in Table 1 .
• As the objective of the study was to evaluate first-and second-line treatments, all patients had received two treatment lines, and 57.2% and 31.6% had received three and four treatment lines, respectively. Ten patients (6.6%) went through exclusive palliative care.
• Sixteen and 21 different regimens were used as first-and second-line treatments, respectively.
Bevacizumab + carboplatin + paclitaxel (32 pts; 21.1%), carboplatin + pemetrexed (31 pts; 20.4%) and cisplatin + pemetrexed (26 pts; 17.1%) were the most frequent first-line regimens, while docetaxel (36 pts; 23.7%), pemetrexed (26 pts; 17.1%) and carboplatin + pemetrexed (20 pts; 13.2%) were the most common second-line regimens. The most commonly used treatments are described in Figure 1 .
• PD-1 inhibitor therapy was used in four of the six research sites and in 20 patients of the study.
Nivolumab was used in 19 of the patients using PD-1 inhibitors therapy. Among the reasons for therapy selection, expanded access to clinical trial drug was the most common (26.3%). Additionally, treatments were evaluated until the most recent data, and most of the patients were treated with Nivolumab after its approval in Brazil (May 2016). Results (Cont.)
• During the duration of treatment, 52% of the patients were hospitalized, 25% had emergency room visits, 95.4% used supplemental medication (median number of medications 13 ), and 50% were submitted to supplemental procedures (median number of procedures 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ). The frequency of resource use per treatment line is described in Table 3 .
• Survival analysis with Cox regression modelling described gender as a prognostic factor in aNSCLC (Figure 2 ). 
Limitations
• This study presents some limitations: retrospective studies often have incomplete data; treatment patterns represent only the practices of physicians who participated in the study; results do not allow conclusions for causal explanations due to cohort study design.
Conclusions
• A high degree of heterogeneity in treatment patterns for NSCLC in these 6 of Brazilian private institutions indicates the lack of a clear effective standard of care for these patients in the preimmunoncology era. The observed high resource use among aNSCLC patients suggests an important economic burden to the private healthcare system. Cost information on these resources would provide an important input into the decision-making process in private healthcare 
